Alto Neuroscience (NYSE:ANRO) Trading 8.8% Higher – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO)’s stock price traded up 8.8% during mid-day trading on Monday . The company traded as high as $24.61 and last traded at $24.78. 167,857 shares were traded during trading, a decline of 34% from the average session volume of 254,385 shares. The stock had previously closed at $22.78.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. BTIG Research increased their price objective on Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a report on Thursday, April 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a report on Monday, December 29th. Chardan Capital reiterated a “buy” rating and set a $30.00 price objective on shares of Alto Neuroscience in a report on Thursday, April 2nd. Finally, Wedbush decreased their price target on Alto Neuroscience from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, April 2nd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Alto Neuroscience Stock Performance

The company has a market capitalization of $823.19 million, a price-to-earnings ratio of -11.79 and a beta of 2.01. The stock has a 50-day moving average price of $19.90 and a 200-day moving average price of $15.60. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.11. As a group, analysts forecast that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Alto Neuroscience in the fourth quarter valued at approximately $304,000. OMERS ADMINISTRATION Corp acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $221,000. Balyasny Asset Management L.P. acquired a new stake in Alto Neuroscience during the 4th quarter worth approximately $198,000. Bridgeway Capital Management LLC lifted its holdings in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after purchasing an additional 25,000 shares during the last quarter. Finally, Invesco Ltd. acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $67,000.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.